Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Exact Sciences Corp's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $20.0B | |
|---|---|---|
| P/E (forward) | 55.2x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.08B | $2.50B | $2.76B | $3.25B | +15.9% |
| Gross profit | $1.42B | $1.76B | $1.92B | $2.26B | +16.7% |
| Operating income | $-618.7M | $-177.3M | $-1.00B | $-169.1M | — |
| Net income | $-623.5M | $-204.1M | $-1.03B | $-207.9M | — |
| EPS (diluted) | $-3.54 | $-1.13 | $-5.59 | $-1.10 | — |
| EBITDA | $-421.1M | $29.3M | $-789.3M | $52.4M | — |
| R&D | $394.2M | $426.9M | $431.2M | $523.0M | +9.9% |
| SG&A | $1.59B | $1.63B | $1.68B | $1.94B | +6.8% |
Recent company headlines from major financial publishers.
Successful Cologuard Plus launch and multi-cancer test expansion drive sustained double-digit growth, scaling margins and expanding terminal multiples.
Continued ~12% revenue growth scaling into strong 70% gross margins. Steady progression toward operating profitability without major multiple compression.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.9% | $144 | $157 | $173 | $193 | $216 |
| 8.9% | $123 | $133 | $144 | $157 | $173 |
| 9.9% | $108 | $115 | $123 | $133 | $144 |
| 10.9% | $95.8 | $101 | $108 | $115 | $123 |
| 11.9% | $86.1 | $90.7 | $95.8 | $101 | $108 |
Upcoming earnings date and setup when available.
The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |